WO2016199798A1 - 運動誘発性の消化管障害の改善剤 - Google Patents
運動誘発性の消化管障害の改善剤 Download PDFInfo
- Publication number
- WO2016199798A1 WO2016199798A1 PCT/JP2016/067005 JP2016067005W WO2016199798A1 WO 2016199798 A1 WO2016199798 A1 WO 2016199798A1 JP 2016067005 W JP2016067005 W JP 2016067005W WO 2016199798 A1 WO2016199798 A1 WO 2016199798A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- exercise
- cystine
- agent
- salt
- present
- Prior art date
Links
- 208000018522 Gastrointestinal disease Diseases 0.000 title claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 106
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims abstract description 99
- 229960003067 cystine Drugs 0.000 claims abstract description 91
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 119
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 59
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 53
- 230000004888 barrier function Effects 0.000 claims description 45
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 41
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 41
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 41
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 41
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 41
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 41
- 229960000310 isoleucine Drugs 0.000 claims description 41
- 239000004474 valine Substances 0.000 claims description 41
- 239000004475 Arginine Substances 0.000 claims description 39
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 39
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 39
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 38
- 150000001413 amino acids Chemical class 0.000 claims description 37
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 36
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 36
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 36
- 229940024606 amino acid Drugs 0.000 claims description 36
- 230000002496 gastric effect Effects 0.000 claims description 36
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 24
- 230000007423 decrease Effects 0.000 claims description 18
- 206010000059 abdominal discomfort Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 238000004806 packaging method and process Methods 0.000 claims description 9
- 230000000694 effects Effects 0.000 abstract description 20
- 230000006866 deterioration Effects 0.000 abstract description 5
- 230000007358 intestinal barrier function Effects 0.000 abstract description 5
- 238000007796 conventional method Methods 0.000 abstract description 2
- 230000037396 body weight Effects 0.000 description 56
- 235000013305 food Nutrition 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 34
- 239000000203 mixture Substances 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 235000021590 normal diet Nutrition 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 15
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 14
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 12
- 238000006731 degradation reaction Methods 0.000 description 12
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 150000007529 inorganic bases Chemical class 0.000 description 11
- 150000007522 mineralic acids Chemical class 0.000 description 11
- 150000007524 organic acids Chemical class 0.000 description 11
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000037406 food intake Effects 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 235000015872 dietary supplement Nutrition 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 229940026510 theanine Drugs 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- 235000011054 acetic acid Nutrition 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 239000001530 fumaric acid Substances 0.000 description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 6
- 239000011976 maleic acid Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 5
- 229910052783 alkali metal Inorganic materials 0.000 description 5
- 150000001340 alkali metals Chemical class 0.000 description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
- 150000001342 alkaline earth metals Chemical class 0.000 description 5
- 150000003863 ammonium salts Chemical class 0.000 description 5
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
- 229940071870 hydroiodic acid Drugs 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910017604 nitric acid Inorganic materials 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 235000006408 oxalic acid Nutrition 0.000 description 5
- 235000019260 propionic acid Nutrition 0.000 description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000004596 appetite loss Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 208000010643 digestive system disease Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000003022 colostrum Anatomy 0.000 description 3
- 235000021277 colostrum Nutrition 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- -1 dialkylethanolamine Chemical compound 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000021056 liquid food Nutrition 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- 208000019017 loss of appetite Diseases 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 210000001578 tight junction Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000002029 Claudin Human genes 0.000 description 1
- 108050009302 Claudin Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 102000003940 Occludin Human genes 0.000 description 1
- 108090000304 Occludin Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 229930182852 proteinogenic amino acid Natural products 0.000 description 1
- 229950004535 rebamipide Drugs 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
Definitions
- the present invention relates to an agent for improving exercise-induced gastrointestinal disorders.
- the digestive tract has not only digestive absorption of ingested food but also a barrier function that prevents foreign substances from entering the body. It is known that a decrease in the barrier function leads to invasion of enteric bacteria into the body, causing inflammation and causing not only a malfunction of the digestive tract but also a general deterioration of the physical condition. In severe cases, bacteria may migrate to the organ and cause multiple organ failure. Such a decrease in the barrier function of the digestive tract is caused by intense exercise (Non-patent Document 1). Although the decrease in gastrointestinal function during exercise is similar to Crohn's disease, ulcerative colitis, and stress-related diseases, the detailed mechanism is unclear.
- barrier function is lowered due to physiological phenomena peculiar to exercise such as blood gathering in muscles and heart and blood supply to the digestive tract is reduced, and body temperature is increased. Since this decrease in barrier function leads to a decrease in athlete's condition and performance, it is important for athletes to maintain the gastrointestinal barrier function.
- Cow colostrum, glutamine, and arginine have been reported to improve exercise-induced degradation of gastrointestinal barrier function.
- cow colostrum it has been reported that stress resistance of the intestinal tract is increased by growth factors such as TGF-1 contained therein (Patent Document 1).
- TGF-1 contained therein
- Non-patent documents 2 and 3 report that exercise-induced degradation of the gastrointestinal barrier function is alleviated by ingesting glutamine or arginine for 1 week.
- the improvement effect of glutamine and arginine on exercise-induced degradation of the gastrointestinal barrier function cannot be said to be sufficient, and there is another problem that glutamine has low stability in an aqueous solution and its use is limited.
- Patent Document 2 reports a supplement that is administered enterally to maintain or restore the intestinal barrier of the intestines of critically ill or chronically ill patients and malnourished people. However, Patent Document 2 does not describe exercise-induced gastrointestinal disorders, nor does it describe that cystine was actually used. In addition, the supplement described in Patent Document 2 is administered enterally and is not taken orally.
- Non-Patent Document 4 reports that oral administration of cystine and theanine before surgery suppresses inflammation of the gastrointestinal tract in a mouse surgery (small intestine manipulation) model.
- the model used in Non-Patent Document 4 is not a model that developed gastrointestinal inflammation due to exercise, but a model that developed gastrointestinal inflammation due to physical injury (small intestine manipulation). There is also no data describing gastrointestinal permeability.
- Non-Patent Document 5 reports that long-distance runners ingested cystine and theanine to suppress immunity reduction during exercise and to relieve muscle damage after exercise. However, improvement in immune decline during exercise is not associated with improvement in exercise-induced gastrointestinal disorders. Non-Patent Document 5 does not describe data evaluated for gastrointestinal permeability.
- Non-Patent Document 6 reports that long-distance runners consumed cystine and theanine to suppress immunity reduction during exercise and to suppress systemic inflammation. However, as described above, improvement in immune decline during exercise is not related to improvement in exercise-induced gastrointestinal disorders. Further, suppression of systemic inflammation does not necessarily improve the degradation of the gastrointestinal barrier function. Non-patent document 6 does not discuss any exercise-induced gastrointestinal disorders.
- JP 2002-513544 A JP-T-2004-513912
- the present invention has been made in view of the above circumstances, and the problem to be solved is for exercise-induced gastrointestinal disorders including exercise-induced gastrointestinal barrier function deterioration,
- An object of the present invention is to provide an ameliorating agent for exercise-induced gastrointestinal disorders that can achieve an improvement effect equal to or higher than that of the prior art.
- cystine is excellent in the action of improving exercise-induced gastrointestinal disorders (eg, gastrointestinal barrier function decline and gastrointestinal upset).
- exercise-induced gastrointestinal disorders eg, gastrointestinal barrier function decline and gastrointestinal upset.
- the present invention has been completed by further research based on the findings.
- the present invention is as follows.
- An agent for improving exercise-induced gastrointestinal dysfunction comprising cystine or a salt thereof as an active ingredient.
- the agent according to [1], wherein the gastrointestinal tract disorder is at least one selected from reduced gastrointestinal barrier function and gastrointestinal upset.
- the agent according to [1] or [2], wherein the content of cystine or a salt thereof is 0.1% by weight or more based on the total amino acids contained.
- the agent according to any one of [1] to [3], wherein the content of cystine or a salt thereof is 6 mg to 12 g per human intake.
- [5] The unit packaging form of a single intake, wherein 6 to 12 g of cystine or a salt thereof is contained in the unit as a single intake, according to any one of [1] to [4] Agent.
- Agent The method according to any one of [1] to [5], further comprising at least one selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine, isoleucine and salts thereof. Agent.
- [15] The agent according to any one of [1] to [13], and the fact that the agent can or should be used to improve exercise-induced gastrointestinal disorders Commercial package, including written description.
- [16] A method for improving exercise-induced gastrointestinal disorders, comprising allowing a subject in need thereof to take an effective amount of an agent containing cystine or a salt thereof as an active ingredient at least once.
- the gastrointestinal tract disorder is at least one selected from reduced gastrointestinal barrier function and gastrointestinal upset.
- the method according to [16] or [17] wherein the content of cystine or a salt thereof in the agent is 0.1% by weight or more based on all amino acids contained in the agent.
- the total of the content of cystine or a salt thereof in the agent and at least one content selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine, isoleucine and salts thereof is the agent [21] The method according to [21], wherein the content is 10% by weight or more based on the total amino acids. [23] (a) The content of cystine or a salt thereof in the agent, and (b) at least one selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine, isoleucine and salts thereof in the agent.
- the agent of the present invention is preferably used for improving exercise-induced gastrointestinal disorders.
- the agent of the present invention is effectively used to improve exercise-induced gastrointestinal barrier function reduction (preferably, small intestine and / or large intestine barrier function) and / or exercise-induced gastrointestinal upset. It is done.
- the agent of the present invention is extremely advantageous because it contains an amino acid rich in dietary experience such as cystine as an active ingredient, and thus has high safety and almost no side effects.
- FIG. 4 is a diagram showing a protocol of Example 2.
- Non-exercise group group that received normal diet and did not exercise
- exercise group group that received normal diet and exercised fatigue for 3 consecutive days
- exercise + 2% cystine group added cystine Group that was ingested and exercised.
- Sed a group in which normal food was ingested and was not exercised
- Ex a group in which normal food was ingested and exercised
- GC + a normal diet to which an amino acid composition containing glutamine and cystine was added
- P ⁇ 0.05 between the different signs of a and b.
- “exercise-induced gastrointestinal tract disorder” refers to a gastrointestinal tract disorder that develops with exercise (particularly intense exercise).
- “violent exercise” refers to exercise for a long time, exercise every day, exercise of relatively high intensity, exercise in a harsh environment such as under high temperature, and the like.
- “Gastrointestinal disorders” refers to tissue damage and functional deterioration in the gastrointestinal tract (pharynx, esophagus, stomach, small intestine (duodenum, jejunum, ileum), large intestine), and symptoms caused by them. And gastrointestinal barrier function decline and gastrointestinal upset.
- a method for determining whether or not a gastrointestinal disorder is exercise-induced for example, a significant increase in TNF- ⁇ cannot be confirmed, but when a gastrointestinal disorder occurs, the gastrointestinal disorder is exercise-induced. It can be determined that there is. Whether or not the gastrointestinal tract disorder is exercise-induced is determined not only from TNF- ⁇ , but also from, for example, an increase in body temperature, blood shortage, inflammation (particularly inflammation in which the increase in TNF- ⁇ is not significant), etc. It may be determined.
- Intracellular pathways contribute to the absorption of nutrients through transporters and channels on the cell membrane.
- the cell-to-cell pathway has selective permeability controlled by adhesion molecules between adjacent cells, which is useful for absorption of minerals such as calcium, as well as intestinal bacteria and diet-derived antigens that exist in large quantities in the lumen.
- adhesion molecules between adjacent cells, which is useful for absorption of minerals such as calcium, as well as intestinal bacteria and diet-derived antigens that exist in large quantities in the lumen.
- it shows a barrier function that does not enter the body.
- the adhesive molecular structure responsible for this selective permeability is a tight junction.
- Tight junctions are large protein complexes that are located in the vicinity of the brush border membrane of the epithelial cell side bottom membrane, and are composed of transmembrane proteins such as occludin and claudin and intracellular lining proteins such as zonula occludens.
- “exercise-induced decrease in gastrointestinal barrier function” means epithelial cells of the digestive tract (pharynx, esophagus, stomach, small intestine (duodenum, jejunum, ileum), large intestine) accompanying exercise (particularly intense exercise).
- Gastrointestinal barrier function deterioration is considered to be caused by, for example, a decrease in blood supply to the gastrointestinal tract during exercise. Moreover, it is thought that a digestive tract barrier function fall is also caused, for example by the raise of body temperature.
- a schematic diagram of the degradation of the gastrointestinal barrier function is shown in FIG. “Exercise-induced degradation of gastrointestinal barrier function” is thought to be mainly due to increased body temperature and decreased blood flow due to exercise.
- stress-related intestinal diseases and inflammatory bowel diseases are caused by inflammation, and these are considered to be different in mechanism and state from exercise-induced gastrointestinal barrier function decline.
- gastrointestinal tract barrier function is reduced or improved, the transition from the gastrointestinal tract to the body is suppressed if the gastrointestinal tract barrier function is maintained normally, but digestion occurs when the gastrointestinal barrier function is reduced.
- a labeled compound having a molecular weight that passes through the tube and enters the blood for example, a molecular weight of about 4000
- measures the amount (concentration) of the labeled compound in the blood can do.
- gastrointestinal upset refers to gastrointestinal upset that develops with exercise (particularly intense exercise).
- gastrointestinal upset is a general term for pathological symptoms that occur in the gastrointestinal tract and pathological symptoms that occur due to a decrease in gastrointestinal function, such as decreased appetite, stomach pain, nausea, Examples include diarrhea.
- “improvement” of exercise-induced gastrointestinal disorders includes, for example, significantly suppressing exercise-induced degradation of the gastrointestinal barrier function during exercise, and during or after exercise-induced exercise in the stomach. Significantly suppresses pain, nausea and digestive ability, significantly reduces appetite loss after exercise, and prevents intestinal bacteria and bacterial toxins from entering the body to alleviate physical condition .
- “improvement” means “prevention or treatment”. “Prevention” of exercise-induced gastrointestinal disorders means preventing or delaying the onset of exercise-induced gastrointestinal disorders, and “treatment” means symptoms of exercise-induced gastrointestinal disorders Or to prevent or delay the progression (aggravation) of symptoms.
- cystine contained as an active ingredient in the agent of the present invention any of L-form, D-form and DL-form can be used, preferably L-form and DL-form, and more preferably L-form.
- Cystine can be used not only in a free form but also in a salt form.
- the term “cystine” in the present invention is a concept including a salt.
- the salt form include acid addition salts and salts with bases, and pharmacologically acceptable salts are preferably selected.
- Specific examples of cystine salts include salts with inorganic bases, salts with inorganic acids, and salts with organic acids.
- Examples of the salt with an inorganic base include a salt with an alkali metal such as sodium, potassium and lithium, a salt with an alkaline earth metal such as calcium and magnesium, and an ammonium salt.
- Examples of the salt with an inorganic acid include salts with hydrohalic acid (hydrochloric acid, hydrobromic acid, hydroiodic acid, etc.), sulfuric acid, nitric acid, phosphoric acid and the like.
- Examples of the salt with an organic acid include salts with formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, maleic acid, fumaric acid, citric acid and the like.
- cystine may be extracted from a naturally occurring animal or plant or the like, or obtained by chemical synthesis, fermentation, enzyme, or genetic recombination.
- the content of cystine is preferably 2.5 mg or more, more preferably 6 mg or more, and still more preferably from the viewpoint of the effect of improving gastrointestinal disorders, per human intake. It is 10 mg or more, and particularly preferably 70 mg or more. Further, from the viewpoint of ease of ingestion, the content is preferably 15 g or less, more preferably 12 g or less, and even more preferably 10 g or less per one human intake.
- the calculation of the content of amino acids such as cystine is carried out after converting the salt into a free form when the amino acid forms a salt.
- “a single intake” is an amount taken or administered at a time.
- the content of cystine is preferably 0.1% by weight or more, more preferably 1% by weight or more with respect to all amino acids contained in the agent of the present invention, from the viewpoint of the effect of improving gastrointestinal disorders. More preferably, it is 3% by weight or more, and particularly preferably 10% by weight or more.
- the content of cystine is preferably 100% by weight or less, more preferably 90% by weight or less, from the viewpoint of the effect of improving gastrointestinal disorders, with respect to all amino acids contained in the agent of the present invention. Particularly preferably, it is 80% by weight or less.
- the content of cystine is preferably the largest or the second largest among all amino acids contained in the agent of the present invention.
- the content of cystine is the largest or the second largest among all amino acids contained in the agent of the present invention, it is possible to exhibit efficient functionality as an active ingredient.
- the agent of the present invention may further contain at least one selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine and isoleucine.
- the agent of the present invention contains at least one selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine and isoleucine in addition to cystine, thereby improving the effects of exercise-induced gastrointestinal disorders Is strengthened.
- glutamine is easily used as an energy source for cells in the digestive tract, it is preferable that the agent of the present invention further contains glutamine in addition to cystine.
- glutamine, serine, histidine, arginine, valine, leucine and isoleucine can be used in any of L-form, D-form and DL-form, respectively, preferably L-form and DL-form. Body, more preferably L-form. These can be used not only in a free form but also in a salt form.
- the terms “glutamine”, “serine”, “histidine”, “arginine”, “valine”, “leucine” and “isoleucine” are also concepts including salts. Examples of the salt form include acid addition salts and salts with bases, and pharmacologically acceptable salts are preferably selected.
- Examples of the salt of glutamine include a salt with an inorganic base, a salt with an inorganic acid, a salt with an organic acid, and the like.
- Examples of the salt with an inorganic base include a salt with an alkali metal such as sodium, potassium and lithium, a salt with an alkaline earth metal such as calcium and magnesium, and an ammonium salt.
- Examples of the salt with an inorganic acid include salts with hydrohalic acid (hydrochloric acid, hydrobromic acid, hydroiodic acid, etc.), sulfuric acid, nitric acid, phosphoric acid and the like.
- Examples of the salt with an organic acid include salts with formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, maleic acid, fumaric acid, citric acid and the like.
- Examples of serine salts include salts with inorganic bases, salts with inorganic acids, and salts with organic acids.
- Examples of the salt with an inorganic base include a salt with an alkali metal such as sodium, potassium and lithium, a salt with an alkaline earth metal such as calcium and magnesium, and an ammonium salt.
- Examples of the salt with an inorganic acid include salts with hydrohalic acid (hydrochloric acid, hydrobromic acid, hydroiodic acid, etc.), sulfuric acid, nitric acid, phosphoric acid and the like.
- Examples of the salt with an organic acid include salts with formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, maleic acid, fumaric acid, citric acid, glutamic acid, aspartic acid and the like.
- Examples of histidine salts include salts with inorganic bases, salts with inorganic acids, and salts with organic acids.
- Examples of the salt with an inorganic base include a salt with an alkali metal such as sodium, potassium and lithium, a salt with an alkaline earth metal such as calcium and magnesium, and an ammonium salt.
- Examples of the salt with an inorganic acid include salts with hydrohalic acid (hydrochloric acid, hydrobromic acid, hydroiodic acid, etc.), sulfuric acid, nitric acid, phosphoric acid and the like.
- Examples of the salt with an organic acid include salts with formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, maleic acid, fumaric acid, citric acid and the like.
- Examples of arginine salts include salts with inorganic bases, salts with inorganic acids, and salts with organic acids.
- Examples of the salt with an inorganic base include a salt with an alkali metal such as sodium, potassium and lithium, a salt with an alkaline earth metal such as calcium and magnesium, and an ammonium salt.
- Examples of the salt with an inorganic acid include salts with hydrohalic acid (hydrochloric acid, hydrobromic acid, hydroiodic acid, etc.), sulfuric acid, nitric acid, phosphoric acid and the like.
- Examples of the salt with an organic acid include salts with formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, maleic acid, fumaric acid, citric acid and the like.
- acids that are added to isoleucine, leucine, and valine to form pharmacologically acceptable salts include inorganic acids such as hydrogen chloride, hydrogen bromide, sulfuric acid, and phosphoric acid; acetic acid, lactic acid, citric acid, tartaric acid, Organic acids such as maleic acid, fumaric acid, monomethyl sulfuric acid and the like can be mentioned.
- Examples of pharmacologically acceptable bases of isoleucine, leucine and valine include, for example, metal hydroxides or carbonates such as sodium, potassium and calcium, or inorganic bases such as ammonia; ethylenediamine, propylenediamine, ethanolamine, monoalkyl Organic bases such as ethanolamine, dialkylethanolamine, diethanolamine, and triethanolamine are listed.
- glutamine, serine, histidine, arginine, valine, leucine and isoleucine are extracted and purified from natural animals and plants, respectively, or by chemical synthesis, fermentation, enzyme, or genetic recombination. Any of those obtained may be used.
- the agent of the present invention contains at least one selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine and isoleucine in addition to cystine
- the glutamine, serine, histidine, arginine, valine, leucine and The content of at least one selected from the group consisting of isoleucine is preferably 0.1% by weight or more with respect to all amino acids contained in the agent of the present invention, from the viewpoints of dosing, stability, and functionality. More preferably, it is 1% by weight or more, and particularly preferably 3% by weight or more.
- At least one content selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine, and isoleucine is a dose, stability, function for all amino acids contained in the agent of the present invention. From the viewpoint of properties, it is preferably 99% by weight or less, more preferably 90% by weight or less, and particularly preferably 80% by weight or less.
- "at least one content selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine and isoleucine” means that the agent of the present invention is glutamine, serine, histidine, arginine, In the case of containing one selected from the group consisting of valine, leucine and isoleucine, it is the content of the one component, and in addition to cystine, the agent of the present invention is glutamine, serine, histidine, arginine, valine, When it contains two or more selected from the group consisting of leucine and isoleucine, it is the total content of the two or more components.
- the agent of the present invention contains at least one selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine and isoleucine in addition to cystine, the glutamine, serine, histidine, arginine, valine, leucine and The content of at least one selected from the group consisting of isoleucine is preferably 10 mg or more, more preferably 50 mg or more, particularly from the viewpoint of ingestion, stability, and functionality, per human intake. Preferably it is 100 mg or more.
- At least one content selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine and isoleucine is preferably 10 g per human intake from the viewpoint of easy intake. Or less, more preferably 5 g or less.
- the agent of the present invention contains at least one selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine and isoleucine in addition to cystine
- the content of cystine, glutamine, serine, histidine and arginine , Valine, leucine and at least one content selected from the group consisting of isoleucine is preferable from the viewpoint of the effect of improving exercise-induced gastrointestinal disorders with respect to all amino acids contained in the agent of the present invention. Is 0.2% by weight or more, more preferably 2% by weight or more, still more preferably 6% by weight or more, and particularly preferably 10% by weight or more.
- the total content of cystine and at least one content selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine and isoleucine is based on all amino acids contained in the agent of the present invention. From the viewpoint of ingestion, stability, and functionality, it is preferably 100% by weight or less, more preferably 95% by weight or less, and particularly preferably 90% by weight or less.
- the agent of the present invention contains at least one selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine and isoleucine in addition to cystine, (a) the content of cystine, and (b)
- the agent of the present invention contains isoleucine, leucine and valine in addition to cystine
- the agent of the present invention preferably contains substantially no non-proteinogenic amino acid other than cystine.
- the agent of the present invention does not substantially contain non-protein constituent amino acids other than cystine, so that even when the dose is limited, it provides a sufficient amount of protein raw materials necessary for exercise and exercise-inducing properties. The ability to improve gastrointestinal disorders can be achieved.
- Non-protein-constituting amino acids other than cystine include, for example, theanine, ornithine, citrulline, taurine, GABA ( ⁇ -aminobutyric acid), etc. Among them, theanine cannot be directly used as a protein raw material. It is preferable that the agent does not substantially contain theanine.
- substantially does not contain non-protein constituent amino acids other than cystine (eg, theanine etc.) means (1) no non-protein constituent amino acids other than cystine, or (2) other than cystine Of non-protein constituent amino acids to the extent that does not affect the effect of the present invention (specifically, generally 28% by weight or less, preferably 20% by weight or less, based on all amino acids contained in the agent of the present invention, More preferably, it is 10% by weight or less, further preferably 1% by weight or less, and particularly preferably 0.1% by weight or less.
- the agent of the present invention can be used in combination with a therapeutic agent for gastrointestinal ulcer (hereinafter sometimes referred to as a concomitant drug).
- a therapeutic agent for gastrointestinal ulcer hereinafter sometimes referred to as a concomitant drug.
- the concomitant drug is not particularly limited as long as it is a therapeutic drug usually used in the treatment of digestive system diseases, and specific examples include rebamipide.
- the agent of the present invention can be used in combination with good bacteria such as lactic acid bacteria and bifidobacteria.
- the good bacteria are not particularly limited, and specific examples include VSL # 3 (registered trademark).
- Examples of the application target of the agent of the present invention include mammals (eg, humans, mice, rats, hamsters, rabbits, cats, dogs, cows, sheep, monkeys, etc.).
- the intake of the agent of the present invention may be appropriately set according to the weight or size of the mammal.
- the agent of the present invention is usually taken orally, but can be administered through routes of administration such as enteral tube administration and administration by infusion according to the symptoms of the application target.
- routes of administration such as enteral tube administration and administration by infusion according to the symptoms of the application target.
- Examples of the dosage form when the agent of the present invention is taken orally include, for example, granules, fine granules, powders, coated tablets, tablets, powders, (micro) capsules, chewables, syrups, juices, liquids , Suspensions, emulsions and the like. Preparation into these dosage forms can be performed by a conventional method.
- various pharmacologically acceptable pharmaceutical substances can be blended as required in the preparation.
- the substance for formulation can be appropriately selected according to the dosage form of the agent of the present invention.
- excipients for example, excipients, diluents, additives, disintegrants, binders, coating agents, lubricants, lubricants, lubricants can be selected.
- specific examples of the pharmaceutical substance include magnesium carbonate, titanium dioxide, saccharides (eg, lactose and mannitol), talc, milk protein, gelatin, starch, cellulose and derivatives thereof, animal and vegetable oils, polyethylene glycol, solvents (For example, sterilized water) and monohydric or polyhydric alcohols (for example, glycerol) and the like.
- the intake amount of the agent of the present invention varies depending on the symptom, age, weight or dosage form, intake method or administration method of the application subject, but when the application subject is an adult, the agent of the present invention is Usually, 0.1 mg / kg body weight to 2 g / kg body weight, preferably 1 mg / kg body weight to 1 g / kg body weight, more preferably 5 mg / kg body weight to 0.2 g / kg body weight can be used. .
- the agent of the present invention contains at least one selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine and isoleucine in addition to cystine, and the subject of application is an adult
- the agent of the present invention Can be used such that at least one selected from the group consisting of glutamine, serine, histidine, arginine, valine, leucine and isoleucine is ingested in the following amounts.
- Glutamine usually 0.1 mg / kg body weight to 5 g / kg body weight per day, preferably 1 mg / kg body weight to 4 g / kg body weight, more preferably 5 mg / kg body weight to 2 g / kg body weight
- Serine usually per day 0.1 mg / kg body weight to 4 g / kg body weight, preferably 1 mg / kg body weight to 2 g / kg body weight, more preferably 5 mg / kg body weight to 1 g / kg body weight
- Histidine Usually 0.1 mg / kg body weight per day 4 g / kg body weight, preferably 1 mg / kg body weight to 2 g / kg body weight, more preferably 5 mg / kg body weight to 1 g / kg body weight
- Arginine Usually 1 mg / kg body weight to 4 g / kg body weight per day, preferably 1 mg / kg body weight kg body weight to 2 g / kg body weight, more preferably 0.02 g / kg body weight to 1
- the agent of the present invention can be used so that the total intake amount of all amino acids per day is usually 0.1 mg / kg body weight to 4 g / kg body weight.
- the agent of the present invention is the sum of the intake of all amino acids per day from the viewpoint of the functionality of the agent of the present invention and the amount of protein that the athlete should take per day.
- it can be used preferably at 0.01 g / kg body weight to 2 g / kg body weight, more preferably 0.05 g / kg body weight to 1 g / kg body weight.
- the intake time of the agent of the present invention is not particularly limited, and may be any time, for example, before the start of exercise, during exercise, or after the end of exercise.
- the intake time of the agent of the present invention is preferably before the start of exercise from the viewpoint that the agent of the present invention is preferably exposed to the digestive tract in advance before starting exercise.
- the number of intakes of the agent of the present invention is not particularly limited, but is at least once (once or twice or more).
- the agent of the present invention is preferably taken at least once before the start of exercise from the viewpoint of ease of use and functionality.
- the agent of the present invention may be taken at least once before starting exercise, and further taken at least once during exercise and / or after the end of exercise.
- the intake period of the agent of the present invention (the period from the first intake to the last intake) is not particularly limited, but is usually 6 hours to 4 weeks, From the viewpoint of exerting an effect of improving exercise-induced gastrointestinal tract disorders, it is preferably 1 day to 2 weeks, more preferably 3 days to 1 week.
- the agent of the present invention is taken 1 to 5 times (preferably 1 to 3 times) per day from 1 day to 2 weeks before the start of exercise (preferably 3 days to 1 week before). Can be used.
- ingested after the end of exercise it can be used so that it is ingested 1 to 3 times immediately after the end of exercise to 24 hours (preferably immediately after to 6 hours).
- cystine or at least one selected from the group consisting of cystine and glutamine, serine, histidine, arginine, valine, leucine and isoleucine is contained in two or more preparations alone or in any combination. Or all may be contained in one formulation.
- the timing at which each preparation is taken may be simultaneous or separate, and the route through which each preparation is taken is the same. It may or may not be.
- an embodiment in which all active ingredients are contained in one preparation is preferable because it can be easily ingested.
- the timing of ingestion can be appropriately determined depending on the type and effect.
- cystine or at least one selected from the group consisting of cystine and glutamine, serine, histidine, arginine, valine, leucine and isoleucine is contained in two or more preparations
- these effective Calculation of component content (content per human intake, content relative to all amino acids contained in the agent of the present invention) and weight ratio is performed by summing the amounts contained in each preparation.
- the agent of the present invention can be used by adding to various foods.
- the said foodstuff is not restrict
- the agent of the present invention can be added to a beverage, and if desired, an appropriate flavor can be added to obtain a drink agent (for example, a soft drink).
- the agent of the present invention can be added to, for example, juice, milk, confectionery, jelly, yogurt, strawberries and the like.
- the “health functional food” includes foods for specified health use and functional foods for nutrition.
- the “special health food” is a food that can indicate that a specific health purpose can be expected, such as improvement of digestive tract disorders.
- “Nutritional functional food” is a food that can indicate the function of the nutritional component when the amount of nutritional component included in the daily intake standard amount conforms to the standards of the upper and lower limits set by the national government. It is.
- Dietary supplements include so-called nutritional supplements or health supplements.
- “food for specified health use” is a food with a label indicating that it is used for applications such as gastrointestinal disorders, and further a document (so-called effect statement) stating that it is used for such applications. Foods that include the above as a package are also included.
- the agent of the present invention can be used by adding it to a concentrated liquid food or a food supplement.
- food supplements When added to food supplements, other ingredients can be added as desired to prepare in the form of tablets, capsules, powders, granules, suspensions, chewables, syrups and the like.
- the “food supplement” in the present invention refers to those ingested for the purpose of supplementing nutrition in addition to those ingested as food, and also includes nutritional supplements and supplements.
- “Concentrated liquid food” is adjusted to a concentration of about 1 kcal / ml, and the qualitative composition of each nutrient is fully taken into consideration so that no significant excess or deficiency of nutrients will occur even after long-term single intake. It is a comprehensive nutritional food (liquid food) designed based on the required amount.
- a food composition for improving exercise-induced gastrointestinal disorders containing cystine as an active ingredient is also provided. Is done.
- the agent of the present invention itself may contain at least one food material and may be used as a food composition.
- the “food composition” in the present invention is a concept that broadly encompasses those that can be taken orally, and includes beverages, seasonings and the like.
- the agent of the present invention can be in a unit packaging form.
- the “unit packaging form” refers to a form in which one unit or two or more units are contained in one package, with a specific amount (for example, a single intake) as one unit.
- the unit packaging form in which the intake amount is 1 unit is referred to as “unit packaging form per intake amount”.
- the packaging used for the unit packaging form can be appropriately selected according to the form of the agent of the present invention, and examples thereof include paper containers, plastic containers, aluminum cans, steel cans, glass bottles, PET bottles, PTP sheets and the like. .
- the present invention can or should be used to improve the agents of the present invention, as well as exercise-induced gastrointestinal disorders (eg, exercise-induced gastrointestinal barrier function decline).
- exercise-induced gastrointestinal disorders eg, exercise-induced gastrointestinal barrier function decline.
- Commercial packages are also provided, including descriptions stating that
- the agent of the present invention can improve exercise-induced gastrointestinal dysfunction by allowing a subject in need thereof to take (administer) an effective amount at least once.
- the agent of the present invention causes exercise-induced degradation of the gastrointestinal barrier function (preferably the small intestine and / or large intestine barrier function) by allowing a subject in need thereof to take an effective amount at least once. ) And / or exercise-induced gastrointestinal upset.
- the present invention relates to exercise-induced gastrointestinal disorders (eg, exercise-induced gastrointestinal tract) comprising ingesting (administering) an effective amount of an agent of the present invention at least once to a subject in need thereof.
- the present invention also provides a method for improving a decrease in barrier function and exercise-induced gastrointestinal upset.
- the method may exclude medical practice.
- medical practice refers to an act of treating, operating or diagnosing a human being performed by a doctor or dentist or under the supervision of a doctor or dentist.
- mice Seven-week-old male CD2F1 mice (Nippon Charles River Co., Ltd.) were grouped into 4 groups (Sed, Ex, Gln + Ex and Cyt + Ex).
- Sed and Ex a normal diet (AIN-93G composition) was used.
- Gln + Ex a normal diet (AIN-93G composition) with glutamine (2%) added
- Cyt + Ex a normal diet (AIN-93G composition) with cystine (2%) added, respectively. Ingested daily. Thereafter, each group was fasted overnight, and Ex, Gln + Ex, and Cyt + Ex were run in a rotating car for 4 hours (speed: 10.5 m / min). Sed continued to fast while Ex, Gln + Ex and Cyt + Ex were running.
- FITC-dextran (average molecular weight 4000; FD4, Sigma Aldrich Japan) was orally administered to each group at a dose of 500 mg / kg body weight, and blood was collected after 1 hour.
- FD4 permeability of FD4 was calculated by measuring the fluorescence intensity in the blood, whereby the FD4 permeability of FD4 was evaluated (FIG. 2).
- the collected blood was centrifuged to obtain plasma, and the obtained plasma was diluted 2-fold with a phosphate buffer, and the excitation wavelength was 485 nm.
- the fluorescence intensity was measured under the condition of a detection wavelength: 535 nm (measuring instrument SPECTRA MAX GEMINI EM Molecular Device Japan).
- FIG. 3 shows the results (between different symbols a, b and c, P ⁇ 0.05).
- the group (Ex) ingested the normal diet and exercised had a higher FD4 concentration in the blood. From this result, it was confirmed that the gastrointestinal barrier function was lowered by running for 4 hours, and a large amount of high molecular weight substance flowed into the blood from the gastrointestinal tract.
- the group (Cyt + Ex) fed and exercising a normal diet supplemented with cystine had a lower FD4 concentration in blood compared to Ex. This result showed that cystine improved exercise-induced gastrointestinal barrier function decline.
- Cyt + Ex had a lower FD4 concentration in the blood compared to the group (Gln + Ex) ingested and exercised a normal diet supplemented with glutamine. From this result, it was found that cystine was more effective in improving exercise-induced gastrointestinal barrier function decline than glutamine at the same dose.
- cystine has an effect of improving exercise-induced loss of appetite. Athletes suffer from gastrointestinal upsets and appetite in scenes where intense training is repeated, such as training camps. Therefore, in the following test, the effect of cystine to improve exercise-induced loss of appetite was examined.
- FIG. 5 shows the results of relative food intake when the food intake of each group before pre-loading fatigue exhaustion (Pre run) is 100% (between the different signs of a and b, P ⁇ 0.05).
- the group (exercise group) ingested normal diet and exercised fatigue continuously for 3 days compared to the group that did not exercise and did not exercise (non-exercise group) On the third day, the food intake was significantly reduced. From these results, it was suggested that gastrointestinal upset (decreased appetite) increased and food consumption decreased due to exhaustion of fatigue for 3 consecutive days.
- cystine improved exercise-induced gastrointestinal upset (decreased appetite).
- FIG. 6 shows the results (between different symbols a and b, P ⁇ 0.05).
- the group (Ex) ingested the normal diet and exercised had a higher FD4 concentration in the blood. From this result, it was confirmed that the gastrointestinal barrier function was lowered by running for 4 hours, and a large amount of high molecular weight substance flowed into the blood from the gastrointestinal tract.
- the agent of the present invention is preferably used for improving exercise-induced gastrointestinal disorders.
- the agent of the present invention is effectively used to improve exercise-induced gastrointestinal barrier function reduction (preferably, small intestine and / or large intestine barrier function) and / or exercise-induced gastrointestinal upset. It is done.
- the agent of the present invention is extremely advantageous because it contains an amino acid rich in dietary experience such as cystine as an active ingredient, and thus has high safety and almost no side effects.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Physiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
しかし、運動誘発性の消化管バリア機能低下に対する、グルタミンおよびアルギニンの改善効果は十分とは言えず、さらにグルタミンに関しては、水溶液中の安定性が低く用途が限られるという問題もあった。
しかし、特許文献2には、運動誘発性の消化管障害に関する記載はなく、実際にシスチンを用いたことも記載されていない。また特許文献2に記載のサプリメントは腸内投与されるものであって、経口的に摂取されるものでない。
しかし、非特許文献4において用いられているモデルは、運動によって消化管の炎症を発症したモデルでなく、物理的な傷害(小腸manipulation)によって消化管の炎症を発症したモデルである。また消化管透過性を評価したデータも記載されていない。
しかし、運動時の免疫低下の改善は、運動誘発性の消化管障害の改善と関連するものでない。また非特許文献5には、消化管透過性について評価したデータも記載されていない。
しかし、上述の通り、運動時の免疫低下の改善は、運動誘発性の消化管障害の改善と関連するものでない。また全身性の炎症を抑制しても、必ずしも消化管バリア機能低下が改善されるわけではない。非特許文献6では、運動誘発性の消化管障害についての検討は一切なされていない。
[1]シスチン又はその塩を有効成分として含有する、運動誘発性の消化管障害の改善剤。
[2]消化管障害が、消化管バリア機能低下及び胃腸の不調から選ばれる少なくとも一つである、[1]記載の剤。
[3]シスチン又はその塩の含有量が、含有される全アミノ酸に対して0.1重量%以上である、[1]又は[2]記載の剤。
[4]シスチン又はその塩の含有量が、ヒトの1回摂取量あたり6mg~12gである、[1]~[3]のいずれか一つに記載の剤。
[5]1回摂取量あたりの単位包装形態からなり、該単位中に、シスチン又はその塩を1回摂取量として6mg~12g含有する、[1]~[4]のいずれか一つに記載の剤。
[6]更に、グルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシン、イソロイシン及びそれらの塩からなる群より選ばれる少なくとも一つを含有する、[1]~[5]のいずれか一つに記載の剤。
[7]シスチン又はその塩の含有量と、グルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシン、イソロイシン及びそれらの塩からなる群より選ばれる少なくとも一つの含有量との合計が、含有される全アミノ酸に対して10重量%以上である、[6]記載の剤。
[8](a)シスチン又はその塩の含有量、並びに、(b)グルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシン、イソロイシン及びそれらの塩からなる群より選ばれる少なくとも一つの含有量の重量比が、(a):(b)=1:0.01~10である、[6]又は[7]記載の剤。
[9]経口的に摂取される、[1]~[8]のいずれか一つに記載の剤。
[10]運動開始前に少なくとも1回摂取される、[1]~[9]のいずれか一つに記載の剤。
[11]運動中又は運動終了後に摂取される、[1]~[10]のいずれか一つに記載の剤。
[12]シスチン又はその塩の含有量が、含有される全アミノ酸の中で最も多いか、又は2番目に多い、[1]~[11]のいずれか一つに記載の剤。
[13]運動誘発性の消化管障害の予防又は治療剤である、[1]~[12]のいずれか一つに記載の剤。
[14][1]~[13]のいずれか一つに記載の剤を含有する食品又は医薬。
[15][1]~[13]のいずれか一つに記載の剤、並びに、当該剤を運動誘発性の消化管障害の改善に使用することができること、又は使用すべきであることを記載した記載物を含む、商業的パッケージ。
[16]シスチン又はその塩を有効成分として含有する剤の有効量を、それを必要とする対象に少なくとも1回摂取させることを含む、運動誘発性の消化管障害の改善方法。
[17]消化管障害が、消化管バリア機能低下及び胃腸の不調から選ばれる少なくとも一つである、[16]記載の方法。
[18]前記剤におけるシスチン又はその塩の含有量が、前記剤に含有される全アミノ酸に対して0.1重量%以上である、[16]又は[17]記載の方法。
[19]前記剤におけるシスチン又はその塩の含有量が、ヒトの1回摂取量あたり6mg~12gである、[16]~[18]のいずれか一つに記載の方法。
[20]前記剤が、1回摂取量あたりの単位包装形態からなり、該単位中に、シスチン又はその塩を1回摂取量として6mg~12g含有する、[16]~[19]のいずれか一つに記載の方法。
[21]前記剤が、更に、グルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシン、イソロイシン及びそれらの塩からなる群より選ばれる少なくとも一つを含有する、[16]~[20]のいずれか一つに記載の方法。
[22]前記剤におけるシスチン又はその塩の含有量と、グルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシン、イソロイシン及びそれらの塩からなる群より選ばれる少なくとも一つの含有量との合計が、前記剤に含有される全アミノ酸に対して10重量%以上である、[21]記載の方法。
[23](a)前記剤におけるシスチン又はその塩の含有量、並びに、(b)前記剤におけるグルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシン、イソロイシン及びそれらの塩からなる群より選ばれる少なくとも一つの含有量の重量比が、(a):(b)=1:0.01~10である、[21]又は[22]記載の方法。
[24]前記剤を経口的に摂取させる、[16]~[23]のいずれか一つに記載の方法。
[25]前記剤を運動開始前に少なくとも1回摂取させる、[16]~[24]のいずれか一つに記載の方法。
[26]前記剤を運動中又は運動終了後に摂取させる、[16]~[25]のいずれか一つに記載の方法。
[27]前記剤におけるシスチン又はその塩の含有量が、前記剤に含有される全アミノ酸の中で最も多いか、又は2番目に多い、[16]~[26]のいずれか一つに記載の方法。
[28]運動誘発性の消化管障害の予防又は治療方法である、[16]~[27]のいずれか一つに記載の方法。
[29]シスチン又はその塩を有効成分として含有する剤の有効量を、それを必要とする対象に少なくとも1回摂取させることを含む、運動誘発性の消化管障害の改善方法(但し、医療行為を除く)。
[30]食品組成物である、[1]~[13]のいずれか一つに記載の剤。
[31]シスチン又はその塩を有効成分として含有する、運動誘発性の消化管障害の改善用食品組成物。
[32]消化管障害が、消化管バリア機能低下及び胃腸の不調から選ばれる少なくとも一つである、[31]記載の食品組成物。
[33]シスチン又はその塩の含有量が、含有される全アミノ酸に対して0.1重量%以上である、[31]又は[32]記載の食品組成物。
[34]シスチン又はその塩の含有量が、ヒトの1回摂取量あたり6mg~12gである、[31]~[33]のいずれか一つに記載の食品組成物。
[35]1回摂取量あたりの単位包装形態からなり、該単位中に、シスチン又はその塩を1回摂取量として6mg~12g含有する、[31]~[34]のいずれか一つに記載の食品組成物。
[36]更に、グルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシン、イソロイシン及びそれらの塩からなる群より選ばれる少なくとも一つを含有する、[31]~[35]のいずれか一つに記載の食品組成物。
[37]シスチンの含有量と、グルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシン、イソロイシン及びそれらの塩からなる群より選ばれる少なくとも一つの含有量との合計が、含有される全アミノ酸に対して10重量%以上である、[36]記載の食品組成物。
[38](a)シスチンの含有量、並びに、(b)グルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシン、イソロイシン及びそれらの塩からなる群より選ばれる少なくとも一つの含有量の重量比が、(a):(b)=1:0.01~10である、[36]又は[37]記載の食品組成物。
[39]運動開始前に少なくとも1回摂取される、[31]~[38]のいずれか一つに記載の食品組成物。
[40]運動中又は運動終了後に摂取される、[31]~[39]のいずれか一つに記載の食品組成物。
[41]シスチン又はその塩の含有量が、含有される全アミノ酸の中で最も多いか、又は2番目に多い、[31]~[40]のいずれか一つに記載の食品組成物。
また、本発明の剤は、シスチン等の食経験が豊富なアミノ酸を有効成分とすることから、安全性が高く副作用がほとんどないため、極めて有利である。
消化管障害が運動誘発性であるか否かの判別方法としては、例えば、TNF-αの有意な上昇は確認できないが、消化管障害が起きている場合、その消化管障害は運動誘発性であると判別し得る。消化管障害が運動誘発性であるか否かの判別は、TNF-αだけでなく、例えば、体温上昇、血液不足、炎症の発生(特に、TNF-αの上昇が顕著ではない炎症)等から判別してもよい。
本発明において「運動誘発性の消化管バリア機能低下」とは、運動(特に、激しい運動)に伴って消化管(咽頭、食道、胃、小腸(十二指腸、空腸、回腸)、大腸)の上皮細胞間のバリアが破綻することをいい、消化管の透過性が亢進して異物、腸内細菌又は腸内細菌が産生する毒素等が消化管を通じて体内に侵入しやすい状態をいう。消化管バリア機能低下は、例えば、運動時に消化管への血液の供給が減少すること等によって引き起こされると考えられている。また消化管バリア機能低下は、例えば体温の上昇等によっても引き起こされると考えられている。消化管バリア機能低下の模式図を図1に示す。
「運動誘発性の消化管バリア機能低下」は、運動による体温上昇や血流低下が主要因だと考えられている。一方、ストレス性の腸疾患や炎症性腸疾患は炎症に起因するものであり、これらと運動誘発性の消化管バリア機能低下とは、メカニズムや状態において異なると考えられる。
また本発明において、「改善」とは、「予防又は治療」を含む意である。運動誘発性の消化管障害の「予防」とは、運動誘発性の消化管障害が発症することを防止又は遅延させることを意味し、「治療」とは、運動誘発性の消化管障害の症状を軽減すること、或いは症状の進行(悪化)を防止又は遅延させることを意味する。
また、シスチンは、遊離体のみならず、塩の形態でも使用することができる。本発明における「シスチン」という用語は塩をも包含する概念である。塩の形態としては、酸付加塩や塩基との塩等を挙げることもでき、薬理上許容される塩を選択することが好ましい。
具体的なシスチンの塩としては、無機塩基との塩、無機酸との塩および有機酸との塩等が挙げられる。無機塩基との塩としては、例えば、ナトリウム、カリウム、リチウム等のアルカリ金属との塩、カルシウム、マグネシウム等のアルカリ土類金属との塩、アンモニウム塩等が挙げられる。無機酸との塩としては、例えば、ハロゲン化水素酸(塩酸、臭化水素酸、ヨウ化水素酸等)、硫酸、硝酸、リン酸等との塩が挙げられる。有機酸との塩としては、例えば、ギ酸、酢酸、プロピオン酸、シュウ酸、コハク酸、マレイン酸、フマル酸、クエン酸等との塩が挙げられる。
本発明において「1回摂取量」とは、1回に摂取又は投与される量である。
グルタミンの塩としては、例えば、無機塩基との塩、無機酸との塩および有機酸との塩等が挙げられる。無機塩基との塩としては、例えば、ナトリウム、カリウム、リチウム等のアルカリ金属との塩、カルシウム、マグネシウム等のアルカリ土類金属との塩、アンモニウム塩等が挙げられる。無機酸との塩としては、例えば、ハロゲン化水素酸(塩酸、臭化水素酸、ヨウ化水素酸等)、硫酸、硝酸、リン酸等との塩が挙げられる。有機酸との塩としては、例えば、ギ酸、酢酸、プロピオン酸、シュウ酸、コハク酸、マレイン酸、フマル酸、クエン酸等との塩が挙げられる。
セリンの塩としては、例えば、無機塩基との塩、無機酸との塩、有機酸との塩等が挙げられる。無機塩基との塩としては、例えば、ナトリウム、カリウム、リチウム等のアルカリ金属との塩、カルシウム、マグネシウム等のアルカリ土類金属との塩、アンモニウム塩等が挙げられる。無機酸との塩としては、例えば、ハロゲン化水素酸(塩酸、臭化水素酸、ヨウ化水素酸等)、硫酸、硝酸、リン酸等との塩が挙げられる。有機酸との塩としては、例えば、ギ酸、酢酸、プロピオン酸、シュウ酸、コハク酸、マレイン酸、フマル酸、クエン酸、グルタミン酸、アスパラギン酸等との塩が挙げられる。
ヒスチジンの塩としては、例えば、無機塩基との塩、無機酸との塩および有機酸との塩等が挙げられる。無機塩基との塩としては、例えば、ナトリウム、カリウム、リチウム等のアルカリ金属との塩、カルシウム、マグネシウム等のアルカリ土類金属との塩、アンモニウム塩等が挙げられる。無機酸との塩としては、例えば、ハロゲン化水素酸(塩酸、臭化水素酸、ヨウ化水素酸等)、硫酸、硝酸、リン酸等との塩が挙げられる。有機酸との塩としては、例えば、ギ酸、酢酸、プロピオン酸、シュウ酸、コハク酸、マレイン酸、フマル酸、クエン酸等との塩が挙げられる。
アルギニンの塩としては、例えば、無機塩基との塩、無機酸との塩および有機酸との塩等が挙げられる。無機塩基との塩としては、例えば、ナトリウム、カリウム、リチウム等のアルカリ金属との塩、カルシウム、マグネシウム等のアルカリ土類金属との塩、アンモニウム塩等が挙げられる。無機酸との塩としては、例えば、ハロゲン化水素酸(塩酸、臭化水素酸、ヨウ化水素酸等)、硫酸、硝酸、リン酸等との塩が挙げられる。有機酸との塩としては、例えば、ギ酸、酢酸、プロピオン酸、シュウ酸、コハク酸、マレイン酸、フマル酸、クエン酸等との塩が挙げられる。
イソロイシン、ロイシンおよびバリンにそれぞれ付加して薬理上許容される塩を形成する酸としては、例えば、塩化水素、臭化水素、硫酸、リン酸等の無機酸;酢酸、乳酸、クエン酸、酒石酸、マレイン酸、フマル酸、モノメチル硫酸等の有機酸が挙げられる。
イソロイシン、ロイシンおよびバリンの薬理上許容される塩基としては、例えば、ナトリウム、カリウム、カルシウム等の金属の水酸化物又は炭酸化物、あるいはアンモニア等の無機塩基;エチレンジアミン、プロピレンジアミン、エタノールアミン、モノアルキルエタノールアミン、ジアルキルエタノールアミン、ジエタノールアミン、トリエタノールアミン等の有機塩基が挙げられる。
シスチン以外の非タンパク質構成アミノ酸としては、例えば、テアニン、オルニチン、シトルリン、タウリン、GABA(γ-アミノ酪酸)等が挙げられ、中でもテアニンは直接的にはタンパク質原料となりえないことから、本発明の剤はテアニンを実質的に含有しないことが好ましい。
本発明において、シスチン以外の非タンパク質構成アミノ酸(例えば、テアニン等)を「実質的に含有しない」とは、(1)シスチン以外の非タンパク質構成アミノ酸を全く含有しない場合、又は(2)シスチン以外の非タンパク質構成アミノ酸を、本発明の効果に影響を与えない程度(具体的には、本発明の剤に含有される全アミノ酸に対して、通常28重量%以下、好ましくは20重量%以下、より好ましくは10重量%以下、更に好ましくは1重量%以下、特に好ましくは0.1重量%以下)に含有する場合のいずれかであることを意味する。
これら剤形への調製は、常法により行い得る。また製剤上の必要に応じて、薬理学的に許容し得る各種の製剤用物質を配合することができる。当該製剤用物質は、本発明の剤の剤形に応じて適宜選択できるが、例えば、賦形剤、希釈剤、添加剤、崩壊剤、結合剤、被覆剤、潤滑剤、滑走剤、滑沢剤、矯味剤、風味剤、甘味剤、可溶化剤等が挙げられる。更に、製剤用物質を具体的に例示すると、炭酸マグネシウム、二酸化チタン、糖類(例えば、ラクトースおよびマンニトール等)、タルク、牛乳蛋白、ゼラチン、澱粉、セルロースおよびその誘導体、動物および植物油、ポリエチレングリコール、溶剤(例えば、滅菌水等)、並びに、一価又は多価アルコール(例えば、グリセロール等)等を挙げることができる。
本発明の剤が、シスチンに加え、グルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシンおよびイソロイシンからなる群より選ばれる少なくとも一つを含有し、且つ、適用対象が成人である場合、本発明の剤は、グルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシンおよびイソロイシンからなる群より選ばれる少なくとも一つが、以下の量で摂取されるように用いられ得る。
グルタミン:1日あたり、通常0.1mg/kg体重~5g/kg体重、好ましくは1mg/kg体重~4g/kg体重、より好ましくは5mg/kg体重~2g/kg体重
セリン:1日あたり、通常0.1mg/kg体重~4g/kg体重、好ましくは1mg/kg体重~2g/kg体重、より好ましくは5mg/kg体重~1g/kg体重
ヒスチジン:1日あたり、通常0.1mg/kg体重~4g/kg体重、好ましくは1mg/kg体重~2g/kg体重、より好ましくは5mg/kg体重~1g/kg体重
アルギニン:1日あたり、通常1mg/kg体重~4g/kg体重、好ましくは1mg/kg体重~2g/kg体重、より好ましくは0.02g/kg体重~1g/kg体重
バリン:1日あたり、通常0.1mg/kg体重~4g/kg体重、好ましくは1mg/kg体重~2g/kg体重、より好ましくは5mg/kg体重~1g/kg体重
ロイシン:1日あたり、通常0.1mg/kg体重~4g/kg体重、好ましくは1mg/kg体重~2g/kg体重、より好ましくは5mg/kg体重~1g/kg体重
イソロイシン:1日あたり、通常1mg/kg体重~4g/kg体重、好ましくは1mg/kg体重~2g/kg体重、より好ましくは5mg/kg体重~1g/kg体重
上記1日あたりの摂取量は、1回で、もしくは2回以上(例えば、2~5回)に分けて摂取することができる。
また本発明の剤の摂取回数は特に制限されないが、少なくとも1回(1回又は2回以上)である。本発明の剤は、利用の簡便性と機能性の観点から、運動開始前に少なくとも1回摂取されることが好ましい。また本発明の剤は、運動開始前に少なくとも1回摂取された後、更に、運動中及び/又は運動終了後に少なくとも1回摂取されてもよい。
本発明の剤の摂取回数が2回以上である場合、本発明の剤の摂取期間(最初の摂取から、最後の摂取までの期間)は特に限定されないが、通常6時間~4週間であり、運動誘発性の消化管障害改善効果を発揮する観点から、好ましくは1日間~2週間であり、より好ましくは3日間~1週間である。一態様として、本発明の剤は、運動開始の1日前~2週間前(好ましくは3日前~1週間前)から、1日あたり1~5回(好ましくは1~3回)摂取されるように用いられ得る。また、運動終了後に摂取する場合には、運動終了の直後~24時間後(好ましくは直後~6時間後)に、1~3回摂取されるように用いられ得る。
本発明において、シスチンが、或いは、シスチンとグルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシンおよびイソロイシンからなる群より選ばれる少なくとも一つとが、二つ以上の製剤に含有されている場合、これらの有効成分の含有量(ヒトの1回摂取量あたりの含有量、本発明の剤に含有される全アミノ酸に対する含有量)や重量比の計算は、各製剤に含有されている量を合計して行うものとする。
また、このような本発明の剤を添加した食品を、保健機能食品又はダイエタリーサプリメントとして提供することも可能である。ここで「保健機能食品」には、特定保健用食品および栄養機能食品なども含まれる。「特定保健用食品」は、例えば、消化管障害の改善など、特定の保健の目的が期待できることを表示できる食品である。また「栄養機能食品」は、1日あたりの摂取目安量に含まれる栄養成分量が、国が定めた上限下限値の規格基準に適合している場合、その栄養成分の機能の表示ができる食品である。「ダイエタリーサプリメント」には、いわゆる栄養補助食品又は健康補助食品などが含まれる。本発明において「特定保健用食品」には、消化管障害などの用途に用いるものであるという表示を付した食品、さらには、かかる用途に用いるものである旨を記載した書類(いわゆる効能書き)などをパッケージとして包含する食品なども含まれるものとする。
当該方法は、医療行為を除くものであってよい。ここで「医療行為」とは、医師又は歯科医師によって、あるいは、医師又は歯科医師の指導監督の下で行われる、ヒトを治療、手術又は診断する行為をいう。
通常はあまり消化管から吸収されない高分子量の物質は、消化管のバリア機能が低下していると腸管を透過し血液中に入っていくことが知られている(図1)。そこで、下記のような試験にて、シスチンの運動誘発性の消化管バリア機能低下を改善する効果を検討した。
運動選手は強化合宿など激しいトレーニングを繰り返すような場面では、胃腸の不調を生じ、食欲が落ちることが知られている。そこで、下記のような試験にて、シスチンの運動誘発性の食欲低下を改善する効果を検討した。
7週齢の雄性CD2F1マウス(日本チャールス・リバー株式会社)を3群(Sed、Ex、GC+Ex)に群分けし、Sed及びExに対しては普通食(AIN-93G組成)を、GC+Exに対しては、グルタミンとシスチン(重量比30:7)から構成されるアミノ酸組成物を3.2%添加した普通食(AIN-93G組成)を、それぞれ7日間摂取させた。その後、各群を一晩絶食させ、Ex、GC+Exは、回転車内で4時間走行させた(速度:10.5m/min)。Ex、GC+Exの走行中、Sedは絶食を継続した。走行終了後、実施例1と同様にFD4の消化管透過性の評価を行った。
また、本発明の剤は、シスチン等の食経験が豊富なアミノ酸を有効成分とすることから、安全性が高く副作用がほとんどないため、極めて有利である。
Claims (12)
- シスチン又はその塩を有効成分として含有する、運動誘発性の消化管障害の改善剤。
- 消化管障害が、消化管バリア機能低下及び胃腸の不調から選ばれる少なくとも一つである、請求項1記載の剤。
- シスチン又はその塩の含有量が、含有される全アミノ酸に対して0.1重量%以上である、請求項1又は2記載の剤。
- シスチン又はその塩の含有量が、ヒトの1回摂取量あたり6mg~12gである、請求項1~3のいずれか1項に記載の剤。
- 1回摂取量あたりの単位包装形態からなり、該単位中に、シスチン又はその塩を1回摂取量として6mg~12g含有する、請求項1~4のいずれか1項に記載の剤。
- 更に、グルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシン、イソロイシン及びそれらの塩からなる群より選ばれる少なくとも一つを含有する、請求項1~5のいずれか1項に記載の剤。
- シスチン又はその塩の含有量と、グルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシン、イソロイシン及びそれらの塩からなる群より選ばれる少なくとも一つの含有量との合計が、含有される全アミノ酸に対して10重量%以上である、請求項6記載の剤。
- (a)シスチン又はその塩の含有量、並びに、(b)グルタミン、セリン、ヒスチジン、アルギニン、バリン、ロイシン、イソロイシン及びそれらの塩からなる群より選ばれる少なくとも一つの含有量の重量比が、(a):(b)=1:0.01~10である、請求項6又は7記載の剤。
- 経口的に摂取される、請求項1~8のいずれか1項に記載の剤。
- 運動開始前に少なくとも1回摂取される、請求項1~9のいずれか1項に記載の剤。
- 運動中又は運動終了後に摂取される、請求項1~10のいずれか1項に記載の剤。
- シスチン又はその塩を有効成分として含有する剤の有効量を、それを必要とする対象に少なくとも1回摂取させることを含む、運動誘発性の消化管障害の改善方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020187000933A KR20180016579A (ko) | 2015-06-10 | 2016-06-08 | 운동 유발성 소화관 장애의 개선제 |
JP2017523666A JP6841223B2 (ja) | 2015-06-10 | 2016-06-08 | 運動誘発性の消化管障害の改善剤 |
BR112017026185A BR112017026185A2 (pt) | 2015-06-10 | 2016-06-08 | agente e método para melhorar um distúrbio gastrointestinal induzido por exercício. |
CA2988563A CA2988563A1 (en) | 2015-06-10 | 2016-06-08 | Ameliorating agent for exercise-induced gastrointestinal disorders |
US15/835,564 US10898456B2 (en) | 2015-06-10 | 2017-12-08 | Ameliorating agent for exercise-induced gastrointestinal disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-117758 | 2015-06-10 | ||
JP2015117758 | 2015-06-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/835,564 Continuation US10898456B2 (en) | 2015-06-10 | 2017-12-08 | Ameliorating agent for exercise-induced gastrointestinal disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016199798A1 true WO2016199798A1 (ja) | 2016-12-15 |
Family
ID=57503827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/067005 WO2016199798A1 (ja) | 2015-06-10 | 2016-06-08 | 運動誘発性の消化管障害の改善剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10898456B2 (ja) |
JP (1) | JP6841223B2 (ja) |
KR (1) | KR20180016579A (ja) |
BR (1) | BR112017026185A2 (ja) |
CA (1) | CA2988563A1 (ja) |
TW (1) | TW201717931A (ja) |
WO (1) | WO2016199798A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002513544A (ja) * | 1998-04-30 | 2002-05-14 | ヌミコ・リサーチ・オーストラリア・プロプライエタリー・リミテッド | 食品組成物およびその使用法 |
JP2003530411A (ja) * | 2000-04-12 | 2003-10-14 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | 遊離アミノ酸含有組成物 |
WO2015167002A1 (ja) * | 2014-04-30 | 2015-11-05 | 味の素株式会社 | 消化管障害を改善する組成物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5536457A (en) * | 1978-09-08 | 1980-03-14 | Ajinomoto Co Inc | Amino acid infusion |
US5719133A (en) * | 1994-09-21 | 1998-02-17 | Novartis Nutrition Ag | Adolescent dietary composition |
DE10057290B4 (de) | 2000-11-17 | 2004-01-08 | Fresenius Kabi Deutschland Gmbh | Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten |
DK175877B1 (da) * | 2002-11-11 | 2005-05-09 | Pharmalett As | Præparater til anvendelse som terapeutisk middel |
WO2007133642A1 (en) * | 2006-05-11 | 2007-11-22 | Garcia Ramon D | Sport drink containing amino acids and carbohydrates |
EP1897451A1 (en) * | 2006-09-08 | 2008-03-12 | SHS International Ltd. | Tasteless nutritional supplement containing free amino acids |
BRPI0814745A2 (pt) * | 2007-08-03 | 2014-10-07 | Aminotech As | Composição de produto. |
WO2010126353A1 (en) * | 2009-04-27 | 2010-11-04 | N.V. Nutricia | Pea-based protein mixture and use thereof in a liquid nutritional composition suitable for enteral feeding |
US20150282506A1 (en) * | 2012-10-31 | 2015-10-08 | Mars, Incorporated | Flavour additives |
WO2017159741A1 (ja) * | 2016-03-16 | 2017-09-21 | 味の素株式会社 | 行動体力向上剤 |
-
2016
- 2016-06-08 JP JP2017523666A patent/JP6841223B2/ja active Active
- 2016-06-08 KR KR1020187000933A patent/KR20180016579A/ko unknown
- 2016-06-08 BR BR112017026185A patent/BR112017026185A2/pt not_active Application Discontinuation
- 2016-06-08 CA CA2988563A patent/CA2988563A1/en not_active Abandoned
- 2016-06-08 WO PCT/JP2016/067005 patent/WO2016199798A1/ja active Application Filing
- 2016-06-08 TW TW105118261A patent/TW201717931A/zh unknown
-
2017
- 2017-12-08 US US15/835,564 patent/US10898456B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002513544A (ja) * | 1998-04-30 | 2002-05-14 | ヌミコ・リサーチ・オーストラリア・プロプライエタリー・リミテッド | 食品組成物およびその使用法 |
JP2003530411A (ja) * | 2000-04-12 | 2003-10-14 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | 遊離アミノ酸含有組成物 |
WO2015167002A1 (ja) * | 2014-04-30 | 2015-11-05 | 味の素株式会社 | 消化管障害を改善する組成物 |
Non-Patent Citations (6)
Also Published As
Publication number | Publication date |
---|---|
JPWO2016199798A1 (ja) | 2018-03-29 |
KR20180016579A (ko) | 2018-02-14 |
CA2988563A1 (en) | 2016-12-15 |
US10898456B2 (en) | 2021-01-26 |
TW201717931A (zh) | 2017-06-01 |
JP6841223B2 (ja) | 2021-03-10 |
BR112017026185A2 (pt) | 2018-08-14 |
US20180098954A1 (en) | 2018-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2356247C2 (ru) | Комбинации и композиции, содержащие жирные кислоты и аминокислоты, их применение для предупреждения, замедления прогрессирования или лечения диабета и связанных с диабетом заболеваний и состояний, способ снижения веса тела млекопитающего, набор | |
US9884033B2 (en) | Amino acid supplementation for a healthy microbiota ecosystem | |
JP2006503105A (ja) | ロイシンに富んだ栄養的組成物 | |
ES2625740T3 (es) | Composiciones nutricionales que incluyen beta-hidroxi-beta-metilbutirato cálcico, fosfopéptido de caseina y proteina | |
EP3091859A1 (en) | Methods for increasing skeletal muscle protein synthesis using green tea extract | |
US20220133782A1 (en) | Methods and compositions for using cinnamaldehyde and zinc for weight management | |
WO2015094767A1 (en) | Methods for maintaining or increasing bodyweight using decaffeinated green tea extract | |
JP6806208B2 (ja) | 消化管障害を改善する組成物 | |
US20170368026A1 (en) | Promotion of healing of intestinal mucosa using proline, serine and threonine | |
WO2016199798A1 (ja) | 運動誘発性の消化管障害の改善剤 | |
US20190247350A1 (en) | Composition for improving decreased absorption in digestive tract, and composition for promoting absorption in digestive tract | |
JP6219588B2 (ja) | 血液酸素運搬能向上剤 | |
WO2017159741A1 (ja) | 行動体力向上剤 | |
JP2010095474A (ja) | カルシウム吸収促進組成物及びカルシウム吸収促進飲食物 | |
CN118176011A (zh) | 用于预防和/或治疗重症监护后综合征(pics)的胶原蛋白水解物 | |
CN116546981A (zh) | 使用至少一种甘氨酸或其衍生物和/或至少一种n-乙酰半胱氨酸或其衍生物以及至少一种百里酚和/或香芹酚的组合物和方法 | |
JP2019058140A (ja) | 栄養組成物 | |
call me Mayo | Protein+ Creatine+ L-Glutamine | |
PRESS | Nutritional management of Crohn's disease with a peptide-based enteral formula |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16807504 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017523666 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2988563 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187000933 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017026185 Country of ref document: BR |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16807504 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 112017026185 Country of ref document: BR Kind code of ref document: A2 Effective date: 20171205 |